Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.62 |
| ▸ | DTYMK | P23919 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.39 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.39 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.39 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.39 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pentadecane SCHEMBL28973560 | 0.89 | TSHR (0.51) | TSHRDTYMKAKR1C3AKR1C2AKR1C1 | |
| SCHEMBL27490189 | 0.88 | TSHR (0.60) | TSHRDTYMKTDP1L3MBTL1CASP6 | |
| SCHEMBL22070445 | 0.85 | DTYMK (0.50) | TSHRDTYMKTDP1L3MBTL1CASP6 | |
| SCHEMBL6304256 | 0.85 | TSHR (0.71) | TSHRDTYMKTDP1L3MBTL1CASP6 | |
| SCHEMBL28162054 | 0.84 | TSHR (0.69) | TSHRDTYMKTDP1L3MBTL1CASP6 | |
| Ammonia Solution, Strong SCHEMBL28332950 | 0.84 | TSHR (0.69) | TSHRDTYMKTDP1L3MBTL1CASP6 | |
| SCHEMBL28842429 | 0.84 | TSHR (0.69) | TSHRDTYMKTDP1L3MBTL1CASP6 | |
| SCHEMBL28194741 | 0.84 | TSHR (0.69) | TSHRDTYMKTDP1L3MBTL1CASP6 | |
| SCHEMBL27741931 | 0.84 | TSHR (0.69) | TSHRDTYMKTDP1L3MBTL1CASP6 | |
| SCHEMBL27852482 | 0.84 | TSHR (0.69) | TSHRDTYMKTDP1L3MBTL1CASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12473267-B2 | Process and intermediate for the preparation of oxetan-2-yl-methanamine | ELI LILLY AND COMPANY (US) | 2025-11-18 | — | — | US | disclosed |
| CN-116332779-B | Preparation method of 3, 4-diaminomethyl benzoate | 苏州敬业医药化工有限公司 | 2025-06-10 | — | — | CN | disclosed |
| EP-4073051-B1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YLMETHANAMINE | LILLY CO ELI (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-116332779-A | Preparation method of 3, 4-diaminomethyl benzoate | 苏州敬业医药化工有限公司 | 2023-06-27 | — | — | CN | disclosed |
| CN-115850083-A | Preparation method of carboxylic acid compounds | 南京正荣医药化学有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-20230013840-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YL-METHANAMINE | ELI LILLY AND COMPANY | 2023-01-19 | — | — | US | disclosed |
| WO-2021118906-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YLMETHANAMINE | ELI LILLY AND COMPANY (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3209646-B1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-10138226-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-11-27 | — | — | US | disclosed |
| CN-108473498-A | Pyrazolo [1,5a] pyrimidine derivatives as IRAK4 conditioning agents | 豪夫迈·罗氏有限公司 | 2018-08-31 | — | — | CN | disclosed |
| US-20170320861-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-09 | — | — | US | disclosed |
| EP-3209646-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2017-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10138226-B2 | Benzimidazol-2-amines as MIDH1 inhibitors | HRH1, HRH2, HRH3 | TSHR 2169/4885DTYMK 1465/4885TDP1 958/4885 |
| US-12473267-B2 | Process and intermediate for the preparation of oxetan-2-yl-methanamine | CYP11B2, CYP11B1, MSMO1 | TSHR 3386/4885DTYMK 1787/4885TDP1 3714/4885 |
| US-20170320861-A1 | BENZIMIDAZOL-2-AMINES AS MIDH1 INHIBITORS | HRH1, HRH2, HRH3 | TSHR 1408/4885DTYMK 1576/4885TDP1 1987/4885 |
| US-20230013840-A1 | PROCESS AND INTERMEDIATE FOR THE PREPARATION OF OXETAN-2-YL-METHANAMINE | CYP11B2, CYP11B1, MSMO1 | TSHR 3386/4885DTYMK 1787/4885TDP1 3714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.